BITS7201A
/ Roche, Light Chain Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 09, 2019
A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers.
(PubMed, BMC Pulm Med)
- P1; "BITS7201A was well tolerated, but was associated with a high incidence of ADA formation."
Biomarker • Clinical • Journal • PK/PD data
1 to 1
Of
1
Go to page
1